OC
WGS icon

Oppenheimer & Co’s GeneDx Holdings WGS Stock Holding History

Oppenheimer & Co’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
7,141
-160
-2% -$9.09K 0.01% 1267
2026
Q1 		$469K Buy
+7,301
New +$666K 0.01% 1212
2025
Q4 		– Sell
-2,201
Closed -$237K – 1751
2025
Q3 		$237K Buy
+2,201
New +$240K ﹤0.01% 1479

Other funds holding WGS

CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Oppenheimer & Co's WGS Position: Q2 2026 in Review

Oppenheimer & Co reduced its GeneDx Holdings (WGS) stake by 2.2% in Q2 2026, selling an estimated $9.09K and leaving 7,141 shares worth $490K. The position accounts for 0.01% of the portfolio, ranked #1267.

Oppenheimer & Co first reported a position in WGS in Q3 2025 and has held it in 3 quarters since. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

  • Oppenheimer & Co held 7,141 shares of GeneDx Holdings worth $490K as of Q2 2026.
  • Oppenheimer & Co sold 160 GeneDx Holdings shares in Q2 2026, an estimated $9.09K.
  • GeneDx Holdings made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1267 holding.
  • Oppenheimer & Co first reported a position in GeneDx Holdings in Q3 2025 and has held it in 3 quarters since.
  • 223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.